Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
+$0.19 today
- Market cap
- $68.98M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 1.40M
ATRA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Atara Biotherapeutics, Inc.NASDAQ: ATRA
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures outflow grows to $0
Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was $0.
Context
- Capital expenditures amounted to 0.0% of revenue in FY2025, down 0.2 pp from a year earlier.
- Capital expenditures increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | +100.0% |
| FY2024 | 2024-12-31 | (246K) | +79.9% |
| FY2023 | 2023-12-31 | (1.22M) | +70.8% |
| FY2022 | 2022-12-31 | (4.19M) | +60.4% |
| FY2021 | 2021-12-31 | (10.58M) | — |
Capital Expenditures vs competitors
How ATRA compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +100.0% is the 5th highest of 10, against a peer median of +100.0%.
- Capital expenditures amounts to 0.0% of revenue for ATRA, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.42M USD | -12.9% | -81.7% | 1042.3% | |
| LTM Mar 2026 | $1.73M USD | -37.7% | -19.2% | 1.1% | |
| LTM Jan 2026 | $578K USD | +2212.0% | -45.4% | 1.0% | |
| LTM Mar 2026 | $532K USD | -86.1% | -40.0% | 0.5% | |
| LTM Mar 2026 | $192.68K USD | +1114.8% | +57.4% | — | |
| LTM Mar 2026 | €114.87K EUR | +178.5% | -11.9% | 391.6% | |
| LTM Mar 2026 | $39K USD | +874.9% | -80.4% | 29.1% | |
| LTM Mar 2026 | $37.26K USD | -9.7% | -60.2% | — | |
| LTM Mar 2026 | $3 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| Peer median (excluding ATRA) | — | +100.0% | -42.7% | 1.0% | |
Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (340.14M) | (228.3M) | (276.13M) | (85.4M) | 32.69M |
| Depreciation & Amortization | 9.35M | 5.65M | 4.83M | 5.05M | 2.38M |
| Deferred Income Tax | 1.79M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 53.87M | 53.84M | 45.39M | 27M | 9.75M |
| Change in Working Capital | 52.58M | (61.47M) | 15.34M | (30.96M) | (104.74M) |
| Accounts Receivables | 264K | (39.24M) | 6.11M | 32.63M | 229K |
| Inventory | 3.34M | (1.59M) | (8.12M) | (4.43M) | 10.66M |
| Accounts Payables | 9.07M | (9.21M) | (3.13M) | 687K | (4.24M) |
| Other Working Capital | 39.91M | (11.44M) | 20.48M | (59.84M) | (111.38M) |
| Other Non-Cash Items | 2.04M | (40.15M) | 17.59M | 15.59M | 8.98M |
| Operating Cash Flow | (220.52M) | (270.43M) | (192.98M) | (68.72M) | (50.94M) |
| Capital Expenditures | (10.58M) | (4.19M) | (1.22M) | (246K) | 0 |
| Acquisitions (Net) | (32.84M) | 0 | 0 | 0 | 948K |
| Purchases of Investments | (301.13M) | (180.59M) | (83.65M) | (19.67M) | (7.89M) |
| Sales of Investments | 333.97M | 292.97M | 208.71M | 28.54M | 25.09M |
| Other Investing Activities | 32.84M | 94.77M | 25K | 0 | 0 |
| Investing Cash Flow | 22.26M | 202.96M | 123.87M | 8.62M | 18.15M |
| Debt Repayment | (254K) | (518K) | (947K) | (892K) | (250K) |
| Common Stock Issued | 98.7M | 21.89M | 2.14M | 59.95M | 16.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.5M | 31.71M | 821K | 223K | (1K) |
| Financing Cash Flow | 103.94M | 53.08M | 2.01M | 59.28M | 16.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (94.32M) | (14.39M) | (67.1M) | (811K) | (16.69M) |
| Free Cash Flow | (231.1M) | (274.62M) | (194.2M) | (68.96M) | (50.94M) |
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.